Canonical and kinase activity-independent mechanisms for extracellular signal-regulated kinase 5 (ERK5) nuclear translocation require dissociation of Hsp90 from the ERK5-Cdc37 complex

Molecular and Cellular Biology

Volumn 33, Issue 8, 2013, Pages 1671-1686

  Erazo, Tatiana ^a   Moreno, Ana ^a   Ruiz Babot, Gerard ^a   Rodríguez Asiain, Arantza ^a   Morrice, Nicholas A ^b   Espadamala, Josep ^a   Bayascas, Jose R ^a   Gómez, Nestor ^a   Lizcano, Jose M ^a  

^a INSTITUT DE NEUROCIÈNCIES   (Spain)

^b BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CALPAIN; CASPASE; CELASTROL; CELL CYCLE PROTEIN 37; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; MDL 128; MITOGEN ACTIVATED PROTEIN KINASE 7; PHOSPHOTRANSFERASE; PROTEASOME; UNCLASSIFIED DRUG; Z VAD;

AMINO ACID SEQUENCE; ARTICLE; CANONICAL ANALYSIS; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CONTROLLED STUDY; DISSOCIATION; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NEOPLASM; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; UBIQUITINATION;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; CELL CYCLE PROTEINS; CELL LINE; CELL NUCLEUS; CELL PROLIFERATION; CHAPERONINS; HEK293 CELLS; HELA CELLS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 7; PHOSPHORYLATION; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; UBIQUITINATION;

EID: 84876318758     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.01246-12     Document Type: Article

References (73)

1. Kyriakis JM, Avruch J. 2001. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 81:807-869.
2. Johnson GL, Lapadat R. 2002. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298:1911-1912.
3. Raman M, Chen W, Cobb MH. 2007. Differential regulation and properties of MAPKs. Oncogene 26:3100-3112.
4. Kato Y, Tapping RI, Huang S, Watson MH, Ulevitch RJ, Lee JD. 1998. Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature 395:713-716.
5. English JM, Pearson G, Baer R, Cobb MH. 1998. Identification of substrates and regulators of the mitogen-activated protein kinase ERK5 using chimeric protein kinases. J. Biol. Chem. 273:3854-3860.
6. Yang CC, Ornatsky OI, McDermott JC, Cruz TF, Prody CA. 1998. Interaction of myocyte enhancer factor 2 (MEF2) with a mitogenactivated protein kinase, ERK5/BMK1. Nucleic Acids Res. 26:4771-4777.
7. Kamakura S, Moriguchi T, Nishida E. 1999. Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J. Biol. Chem. 274: 26563-26571.
8. Lee JD, Ulevitch RJ, Han J. 1995. Primary structure of BMK1: a new mammalian map kinase. Biochem. Biophys. Res. Commun. 213:715-724.
9. Zhou G, Bao ZQ, Dixon JE. 1995. Components of a new human protein kinase signal transduction pathway. J. Biol. Chem. 270:12665-12669.
10. Sohn SJ, Sarvis BK, Cado D, Winoto A. 2002. ERK5 MAPK regulates embryonic angiogenesis and acts as a hypoxia-sensitive repressor of vascular endothelial growth factor expression. J. Biol. Chem. 277:43344-43351.
11. Regan CP, Li W, Boucher DM, Spatz S, Su MS, Kuida K. 2002. Erk5 null mice display multiple extraembryonic vascular and embryonic cardiovascular defects. Proc. Natl. Acad. Sci. U. S. A. 99:9248-9253.
12. Yan L, Carr J, Ashby PR, Murry-Tait V, Thompson C, Arthur JS. 2003. Knockout of ERK5 causes multiple defects in placental and embryonic development. BMC Dev. Biol. 3:11. doi:10.1186/1471-213X-3-11.
13. Wang X, Merritt AJ, Seyfried J, Guo C, Papadakis ES, Finegan KG, Kayahara M, Dixon J, Boot-Handford RP, Cartwright EJ, Mayer U, Tournier C. 2005. Targeted deletion of mek5 causes early embryonic death and defects in the extracellular signal-regulated kinase 5/myocyte enhancer factor 2 cell survival pathway. Mol. Cell. Biol. 25:336-345.
14. Kasler HG, Victoria J, Duramad O, Winoto A. 2000. ERK5 is a novel type of mitogen-activated protein kinase containing a transcriptional activation domain. Mol. Cell. Biol. 20:8382-8389.
15. Chiariello M, Marinissen MJ, Gutkind JS. 2000. Multiple mitogenactivated protein kinase signaling pathways connect the cot oncoprotein to the c-jun promoter and to cellular transformation. Mol. Cell. Biol. 20:1747-1758.
16. Borges J, Pandiella A, Esparis-Ogando A. 2007. Erk5 nuclear location is independent on dual phosphorylation, and favours resistance to TRAILinduced apoptosis. Cell Signal. 19:1473-1487.
17. Pearl LH, Prodromou C. 2006. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu. Rev. Biochem. 75:271-294.
18. McClellan AJ, Xia Y, Deutschbauer AM, Davis RW, Gerstein M, Frydman J. 2007. Diverse cellular functions of the Hsp90 molecular chaperone uncovered using systems approaches. Cell 131:121-135.
19. Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW, Pearl LH. 1997. Identification and structural characterization of the ATP/ADPbinding site in the Hsp90 molecular chaperone. Cell 90:65-75.
20. Neckers L, Workman P. 2012. Hsp90 molecular chaperone inhibitors: are we there yet? Clin. Cancer Res. 18:64-76.
21. Kimura Y, Rutherford SL, Miyata Y, Yahara I, Freeman BC, Yue L, Morimoto RI, Lindquist S. 1997. Cdc37 is a molecular chaperone with specific functions in signal transduction. Genes Dev. 11:1775-1785.
22. Roe SM, Ali MM, Meyer P, Vaughan CK, Panaretou B, Piper PW, Prodromou C, Pearl LH. 2004. The mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37). Cell 116:87-98.
23. Karnitz LM, Felts SJ. 2007. Cdc37 regulation of the kinome: when to hold 'em and when to fold 'em. Sci. STKE 2007:pe22. doi:10.1126/stke.3852007pe22.
24. Gray PJ, Jr, Stevenson MA, Calderwood SK. 2007. Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells. Cancer Res. 67:11942-11950.
25. Gray PJ, Jr, Prince T, Cheng J, Stevenson MA, Calderwood SK. 2008. Targeting the oncogene and kinome chaperone CDC37. Nat. Rev. Cancer 8:491-495.
26. Smith JR, Clarke PA, de Billy E, Workman P. 2009. Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors. Oncogene 28:157-169.
27. Rigaut G, Shevchenko A, Rutz B, Wilm M, Mann M, Seraphin B. 1999. A generic protein purification method for protein complex characterization and proteome exploration. Nat. Biotechnol. 17:1030-1032.
28. Mody N, Campbell DG, Morrice N, Peggie M, Cohen P. 2003. An analysis of the phosphorylation and activation of extracellular-signalregulated protein kinase 5 (ERK5) by mitogen-activated protein kinase kinase 5 (MKK5) in vitro. Biochem. J. 372:567-575.
29. Zheng Q, Yin G, Yan C, Cavet M, Berk BC. 2004. 14-3-3beta binds to big mitogen-activated protein kinase 1 (BMK1/ERK5) and regulates BMK function. J. Biol. Chem. 279:8787-8791.
30. Grbovic OM, Basso AD, Sawai A, Ye Q, Friedlander P, Solit D, Rosen N. 2006. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc. Natl. Acad. Sci. U. S. A. 103:57-62.
31. Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N. 2002. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J. Biol. Chem. 277:39858-39866.
32. Zsebik B, Citri A, Isola J, Yarden Y, Szollosi J, Vereb G. 2006. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Immunol. Lett. 104: 146-155.
33. Prince T, Sun L, Matts RL. 2005. Cdk2: a genuine protein kinase client of Hsp90 and Cdc37. Biochemistry 44:15287-15295.
34. Lizcano JM, Alessi DR. 2002. The insulin signalling pathway. Curr. Biol. 12:R236 -R238.
35. Kondoh K, Terasawa K, Morimoto H, Nishida E. 2006. Regulation of nuclear translocation of extracellular signal-regulated kinase 5 by active nuclear import and export mechanisms. Mol. Cell. Biol. 26:1679-1690.
36. Iñesta-Vaquera FA, Campbell DG, Tournier C, Gomez N, Lizcano JM, Cuenda A. 2010. Alternative ERK5 regulation by phosphorylation during the cell cycle. Cell Signal. 22:1829-1837.
37. Zhang T, Hamza A, Cao X, Wang B, Yu S, Zhan CG, Sun D. 2008. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol. Cancer Ther. 7:162-170.
38. Stepanova L, Finegold M, DeMayo F, Schmidt EV, Harper JW. 2000. The oncoprotein kinase chaperone CDC37 functions as an oncogene in mice and collaborates with both c-myc and cyclin D1 in transformation of multiple tissues. Mol. Cell. Biol. 20:4462-4473.
39. Terasawa K, Okazaki K, Nishida E. 2003. Regulation of c-Fos and Fra-1 by the MEK5-ERK5 pathway. Genes Cells 8:263-273.
40. Morimoto H, Kondoh K, Nishimoto S, Terasawa K, Nishida E. 2007. Activation of a C-terminal transcriptional activation domain of ERK5 by autophosphorylation. J. Biol. Chem. 282:35449-35456.
41. Yang Q, Deng X, Lu B, Cameron M, Fearns C, Patricelli MP, Yates JR, III, Gray NS, Lee JD. 2010. Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell 18:258-267.
42. Mehta PB, Jenkins BL, McCarthy L, Thilak L, Robson CN, Neal DE, Leung HY. 2003. MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation,MMP-9expression and invasion. Oncogene 22:1381-1389.
43. McCracken SR, Ramsay A, Heer R, Mathers ME, Jenkins BL, Edwards J, Robson CN, Marquez R, Cohen P, Leung HY. 2008. Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer. Oncogene 27:2978-2988.
44. Ramsay AK, McCracken SR, Soofi M, Fleming J, Yu AX, Ahmad I, Morland R, Machesky L, Nixon C, Edwards DR, Nuttall RK, Seywright M, Marquez R, Keller E, Leung HY. 2011. ERK5 signalling in prostate cancer promotes an invasive phenotype. Br. J. Cancer 104:664-672.
45. Schwarze SR, Fu VX, Jarrard DF. 2003. Cdc37 enhances proliferation and is necessary for normal human prostate epithelial cell survival. Cancer Res. 63:4614-4619.
46. Truman AW, Millson SH, Nuttall JM, King V, Mollapour M, Prodromou C, Pearl LH, Piper PW. 2006. Expressed in the yeast Saccharomyces cerevisiae, human ERK5 is a client of the Hsp90 chaperone that complements loss of the Slt2p (Mpk1p) cell integrity stress-activated protein kinase. Eukaryot. Cell 5:1914-1924.
47. Citri A, Harari D, Shohat G, Ramakrishnan P, Gan J, Lavi S, Eisenstein M, Kimchi A, Wallach D, Pietrokovski S, Yarden Y. 2006. Hsp90 recognizes a common surface on client kinases. J. Biol. Chem. 281:14361-14369.
48. Boudeau J, Deak M, Lawlor MA, Morrice NA, Alessi DR. 2003. Heatshock protein 90 and Cdc37 interact with LKB1 and regulate its stability. Biochem. J. 370:849-857.
49. Shang L, Tomasi TB. 2006. The heat shock protein 90-CDC37 chaperone complex is required for signaling by types I and II interferons. J. Biol. Chem. 281:1876-1884.
50. Nomura M, Nomura N, Yamashita J. 2005. Geldanamycin-induced degradation of Chk1 is mediated by proteasome. Biochem. Biophys. Res. Commun. 335:900-905.
51. De Nardo D, Masendycz P, Ho S, Cross M, Fleetwood AJ, Reynolds EC, Hamilton JA, Scholz GM. 2005. A central role for the Hsp90. Cdc37 molecular chaperone module in interleukin-1 receptor-associatedkinase- dependent signaling by toll-like receptors.J. Biol. Chem. 280:9813-9822.
52. Xu W, Yuan X, Xiang Z, Mimnaugh E, Marcu M, Neckers L. 2005. Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex. Nat. Struct. Mol. Biol. 12:120-126.
53. Jeffrey PD, Russo AA, Polyak K, Gibbs E, Hurwitz J, Massague J, Pavletich NP. 1995. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 376:313-320.
54. Esparís-Ogando A, Díaz-Rodriguez E, Montero JC, Yuste L, Crespo P, Pandiella A. 2002. Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2. Mol. Cell. Biol. 22:270-285.
55. Kato Y, Kravchenko VV, Tapping RI, Han J, Ulevitch RJ, Lee JD. 1997. BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. EMBO J. 16:7054-7066.
56. Raviv Z, Kalie E, Seger R. 2004. MEK5 and ERK5 are localized in the nuclei of resting as well as stimulated cells, while MEKK2 translocates from the cytosol to the nucleus upon stimulation. J. Cell Sci. 117:1773-1784.
57. Díaz-Rodríguez E, Pandiella A. 2010. Multisite phosphorylation of Erk5 in mitosis. J. Cell Sci. 123:3146-3156.
58. Picard D. 2006. Chaperoning steroid hormone action. Trends Endocrinol. Metab. 17:229-235.
59. Lyu J, Wesselschmidt RL, Lu W. 2009. Cdc37 regulates Ryk signaling by stabilizing the cleaved Ryk intracellular domain. J. Biol. Chem. 284: 12940-12948.
60. Stepanova L, Yang G, DeMayo F, Wheeler TM, Finegold M, Thompson TC, Harper JW. 2000. Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia. Oncogene 19:2186-2193.
61. Pang X, Yi Z, Zhang J, Lu B, Sung B, Qu W, Aggarwal BB, Liu M. 2010. Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res. 70: 1951-1959.
62. Montero JC, Ocana A, Abad M, Ortiz-Ruiz MJ, Pandiella A, Esparis-Ogando A. 2009. Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target. PLoS One 4:e5565. doi:10.1371/journal.pone.0005565.
63. Al-Hakim AK, Goransson O, Deak M, Toth R, Campbell DG, Morrice NA, Prescott AR, Alessi DR. 2005. 14-3-3 cooperates with LKB1 to regulate the activity and localization of QSK and SIK. J. Cell Sci. 118:5661-5673.
64. Hinz M, Broemer M, Arslan SC, Otto A, Mueller EC, Dettmer R, Scheidereit C. 2007. Signal responsiveness of IkappaB kinases is deter- mined by Cdc37-assisted transient interaction with Hsp90. J. Biol. Chem. 282:32311-32319.
65. Papapetropoulos A, Zhou Z, Gerassimou C, Yetik G, Venema RC, Roussos C, Sessa WC, Catravas JD. 2005. Interaction between the 90- kDa heat shock protein and soluble guanylyl cyclase: physiological significance and mapping of the domains mediating binding. Mol. Pharmacol. 68:1133-1141.
66. Belova L, Brickley DR, Ky B, Sharma SK, Conzen SD. 2008. Hsp90 regulates the phosphorylation and activity of serum- and glucocorticoidregulated kinase-1. J. Biol. Chem. 283:18821-18831.
67. Schimmel J, Larsen KM, Matic I, van Hagen M, Cox J, Mann M, Andersen JS, Vertegaal AC. 2008. The ubiquitin-proteasome system is a key component of the SUMO-2/3 cycle. Mol. Cell. Proteomics 7:2107-2122.
68. Rodríguez-Asiain A, Ruiz-Babot G, Romero W, Cubi R, Erazo T, Biondi RM, Bayascas JR, Aguilera J, Gomez N, Gil C, Claro E, Lizcano JM. 2011. Brain specific kinase-1 BRSK1/SAD-B associates with lipid rafts: modulation of kinase activity by lipid environment. Biochim. Biophys. Acta 1811:1124-1135.
69. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254.
70. Lizcano JM, Deak M, Morrice N, Kieloch A, Hastie CJ, Dong L, Schutkowski M, Reimer U, Alessi DR. 2002. Molecular basis for the substrate specificity of NIMA-related kinase-6 (NEK6). Evidence that NEK6 does not phosphorylate the hydrophobic motif of ribosomal S6 protein kinase and serum- and glucocorticoid-induced protein kinase in vivo. J. Biol. Chem. 277:27839-27849.
71. Williamson BL, Marchese J, Morrice NA. 2006. Automated identification and quantification of protein phosphorylation sites by LC/MS on a hybrid triple quadrupole linear ion trap mass spectrometer. Mol. Cell. Proteomics 5:337-346.
72. Lizcano JM, Alrubaie S, Kieloch A, Deak M, Leevers SJ, Alessi DR. 2003. Insulin-induced Drosophila S6 kinase activation requires phosphoinositide 3-kinase and protein kinase B. Biochem. J. 374:297-306.
73. Tatham MH, Rodriguez MS, Xirodimas DP, Hay RT. 2009. Detection of protein SUMOylation in vivo. Nat. Protoc. 4:1363-1371.